Lantheus (NASDAQ:LNTH) Posts Quarterly Earnings Results, Beats Estimates By $0.45 EPS

Lantheus (NASDAQ:LNTH) issued its quarterly earnings results on Thursday. The medical equipment provider reported $1.68 earnings per share for the quarter, topping analysts’ consensus estimates of $1.23 by $0.45, FiscalAI reports. Lantheus had a net margin of 17.28% and a return on equity of 29.26%. The company had revenue of $389.91 million during the quarter, compared to the consensus estimate of $355.74 million. During the same quarter in the prior year, the firm posted $1.27 EPS. The firm’s quarterly revenue was up 1.5% on a year-over-year basis.

Lantheus Price Performance

Shares of NASDAQ LNTH traded down $0.09 during mid-day trading on Friday, hitting $100.61. 1,575,979 shares of the stock traded hands, compared to its average volume of 1,090,931. The company has a market cap of $6.57 billion, a PE ratio of 24.78 and a beta of 0.01. Lantheus has a twelve month low of $50.15 and a twelve month high of $111.86. The company has a debt-to-equity ratio of 0.42, a current ratio of 3.25 and a quick ratio of 2.89. The firm has a 50 day simple moving average of $100.27 and a two-hundred day simple moving average of $92.06.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. B. Riley Financial cut shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Monday, August 17th. Brookline Capital Markets cut Lantheus from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Mizuho cut Lantheus from an “outperform” rating to a “neutral” rating and cut their target price for the stock from $115.00 to $109.00 in a research note on Tuesday, October 13th. Truist Financial downgraded Lantheus from a “buy” rating to a “hold” rating and reduced their target price for the company from $125.00 to $102.50 in a report on Monday, August 3rd. Finally, TD Cowen lowered Lantheus from a “buy” rating to a “hold” rating and decreased their price target for the company from $110.00 to $102.50 in a research note on Monday, August 3rd. Three investment analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $107.44.

About Lantheus

Lantheus Holdings, Inc is a diagnostic imaging and radiopharmaceutical company that develops, manufactures and commercializes products used to help physicians detect, characterize and monitor disease. Its portfolio supports imaging in areas including oncology, cardiology and other medical specialties.

The company’s products include DEFINITY, an ultrasound-enhancing agent used in cardiac and other ultrasound examinations, and PYLARIFY, a prostate-specific membrane antigen (PSMA) PET imaging agent used to help identify and manage prostate cancer.